Area of research
Epidemiology · Hepatology
Research interest
Research interests include Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, and Liver Diseases and Immunity.
Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
IP10 and Anti-HBc can Predict Virological Relapse and HBsAg Loss in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Discontinuation
HBsAg ≤ 135 IU/mL or HBcrAg ≤ 3.6 logU/mL was associated with HBsAg loss after nucleos(t)ide analogue cessation
Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis
HBeAg-positive patients with HBsAg < 135IU/ml or HBcrAg < 3.6logU/ml have more chance to be HBsAg loss after nucleos (t)ide analogue cessation
The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease
Single-cell immune profiling reveals distinct immune response in asymptomatic COVID-19 patients
HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation
Longitudinal single-cell immune profiling revealed distinct innate immune response in asymptomatic COVID-19 patients
Clinical features of hepatitis B patients at immune‐tolerance phase with basal core promoter and/or precore mutations
Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir
Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B
On‐treatment changes of serum <i>Wisteria floribunda</i> agglutinin‐positive Mac‐2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add‐on therapy
Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients
[Qualitative pathological assessment of liver fibrosis regression after antiviral therapy in patients with chronic hepatitis B].
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B
Tim-3 suppression combined with TLR3 activation enhances antiviral immune response in patients with chronic HCV infection
Individualized treatment strategies and predictors of virological response for chronic hepatitis C: a multicenter prospective study from China.
PubMed 2015cited by 3position: middle
Regulatory Phenotype, PD-1 and TLR3 Expression in T Cells and Monocytes from HCV Patients Undergoing Antiviral Therapy: A Randomized Clinical Trial
[Study of using an individualized treatment strategy to treat patients with chronic hepatitis C].